We are an innovative pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and “cannabinoid-like” molecules. We have an interest is botanically derived cannabis-based medicines and also single molecule medicines. Interest in producing cannabinoid and “cannabinoid-like"...
Our Focus
UNMET MEDICAL NEEDS
DEVELOPING TREATMENTS
TO IMPROVE PEOPLES LIVES
We are developing treatments for a variety of clinical indications, with a focus on conditions where there is a high unmet medical need. Specifically, we are looking to develop our products:
- from cannabis-based extracts
- from single chemically-synthesized molecules inspired by single components
INNOVATION
AIMING FOR BETTER
TREATMENTS THROUGH INNOVATION
Our approach will allow us to not only build on the intellectual property that we currently hold, but to build on the knowledge and experience that we have gained from years of research and development experience of cannabis-based medicines at GW Pharmaceuticals (which was sold to Jazz Pharmaceuticals in May 2021 for $7.2 billion US dollars). We are focusing on 2 main clinical indications with 2 separate product types:
- Bladder Pain Syndrome
- Treatment-resistant focal seizures in adults
NEW MOLECULES, LOW-COST OF GOODS AND GROUND BREAKING DRUG DELIVERY SYSTEMS
Our intent is to become a leading pharmaceutical company focused on the capital-efficient advancement cannabinoid and cannabinoid-like innovative drug development candidates; whilst targeting the unmet medical need across a range of therapeutic areas.
Our strategy is to utilize our significant knowledge and experience to develop medicines in the cannabis-based medicines and the cannabinoid medicines sector. Our strategy is to focus on botanically-derived drug products or chemically synthesized modified-stilbenoid “hybrid” molecules utilizing extracts or compounds which are already known to be safe and tolerable (individually) in humans, and allowing us to use our knowledge and experience to risk mitigate the safety profiles of such candidates. By starting with a clinical focus (“what can humans tolerate”) – rather than identifying a receptor target and potent molecule synthesis to fit the target – and focusing on the clinical end of the development we are aiming to minimize the risk of product failure due to toxicity when creating these “hybrids”. Clearly the development candidates will need to go through the usual manufacturing, preclinical and clinical steps that all pharmaceutical drug candidates go through, but by employing such a risk-mitigation approach, we aim to achieve financial inflexion points quickly and as cost-effectively as possible, whilst producing new pharmaceutical products with good intellectual property protection and generating significant shareholder value.
IMPACTS
PHARMACEUTICAL DEVELOPMENT
LOW COST OF GOODS
IMPROVED DRUG DELIVERY
Developing cannabinoid and cannabinoid-like medicines across a range of indications for humans and animals.
IMPROVED DRUG DELIVERY
LOW COST OF GOODS
IMPROVED DRUG DELIVERY
Our exclusive license with Nano4M Ltd seeks to utilize the nano-formulation use of nano-formulation technologies to greatly improve the bio-availability of both the cannabinoids and cannabinoid-like molecules.
LOW COST OF GOODS
LOW COST OF GOODS
LOW COST OF GOODS
Achieving a low cost of goods for GMP grade Active Pharmaceutical Ingredient (API) means that the company will be able to service high volume indications, as well as orphan indications.
News
July 30, 2024
Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential
NEW YORK and SANTA BARBARA, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck. The updated presentation provides an in-depth look at the company’s strategic vision, scientific advancements, and growth potential as it progresses towards the development of next-generation cannabinoid medicines.
The global cannabis pharmaceuticals market size was estimated at USD 3.4 billion in 2023 and is anticipated to grow at a CAGR of 53.3% from 2024 to 2030.
The investor deck is now available on Phytanix Bio’s website:
Key Highlights of the Investor Deck Include:
• Strategic Vision and Mission: An overview of Phytanix Bio’s commitment to developing innovative therapies targeting serious unmet medical needs using cannabinoid and cannabinoid-like molecules.
• Scientific and Clinical Progress: Detailed updates on the company’s preclinical studies, research collaborations, and upcoming clinical milestones.
• Intellectual Property Portfolio: Insights into Phytanix Bio’s exclusive cannabinoid and cannabinoid-like medicine intellectual property, including patents and proprietary technologies.
• Management Team: Profiles of the experienced leadership team, including CEO Barrett Evans, COO Colin Stott, and Chief Legal Officer Dominic Schiller, all former key members of GW Pharmaceuticals.
• Market Opportunities: Analysis of the market potential for Phytanix Bio’s lead product candidates, including treatments for treatment-resistant facial seizures and Painful Bladder Syndrome (PBS).
• Financial Overview: Information on the company’s financial position, recent funding, and future financing strategies.
Barrett Evans, CEO of Phytanix Bio, stated, “We are excited to share our new investor deck, which provides a comprehensive overview of Phytanix Bio’s vision and progress. Our team is dedicated to advancing our pipeline of cannabinoid-based medicines, and this presentation outlines our path forward and the significant opportunities ahead.”
About Phytanix Bio
Phytanix Bio is a preclinical stage pharmaceutical company specializing in the development of medicines derived from cannabinoid and cannabinoid-like active ingredients. Founded by former members of GW Pharmaceuticals, Phytanix Bio leverages its team’s extensive experience and intellectual property to create innovative therapies aimed at addressing significant unmet medical needs.
About Chain Bridge I
Phytanix Bio has entered into a Business Combination Agreement with Chain Bridge I (Nasdaq: CBRG), a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Important Information About the Proposed Merger and Where to Find It
CBRG intends to file with the SEC a registration statement on Form S-4 with a proxy statement containing information about the proposed transaction and the respective businesses of Phytanix Bio and CBRG. CBRG will mail a final prospectus and definitive proxy statement and other relevant documents after the SEC completes its review. CBRG shareholders are urged to read the preliminary prospectus and proxy statement and any amendments thereto and the final prospectus and definitive proxy statement in connection with the solicitation of proxies for the special meeting to be held to approve the proposed transaction, because these documents will contain important information about CBRG, Phytanix Bio, and the proposed transaction. The final prospectus and definitive proxy statement will be mailed to shareholders of CBRG as of a record date to be established for voting on the proposed transaction. Shareholders of CBRG will also be able to obtain a free copy of the proxy statement, as well as other filings containing information about CBRG without charge, at the SEC’s website (www.sec.gov) or by calling 1-800-SEC-0330. Copies of the proxy statement and CBRG other filings with the SEC can also be obtained, without charge, by directing a request to Chain Bridge I, 8 the Green, #17538, Dover Delaware, Attention: CEO.
Participants in Solicitation
Phytanix Bio, CBRG, and their respective directors and executive officers, may be deemed participants in the solicitation of proxies of CBRG’s shareholders in respect of the proposed Business Combination. Information about the directors and executive officers of CBRG and their ownership is set forth in CBRG’s filings with the SEC, including its prospectus relating to its initial public offering, which was filed with the SEC on November 12, 2021. CBRG’s shareholders and other interested persons may obtain more detailed information about the names and interests of the directors and officers of Phytanix Bio and CBRG in the Business Combination will be set forth in CBRG’s filings with the SEC, including the preliminary proxy statement/prospectus and the amendments thereto, the definitive proxy statement/prospectus, and other documents filed with the SEC. These documents can be obtained free of charge from the sources specified above and at the SEC’s web site at www.sec.gov.
This press release does not contain all the information that should be considered concerning the Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. Before making any voting or investment decision, investors and security holders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed Business Combination as they become available because they will contain important information about the proposed Business Combination.
No Offer of Solicitation
This press release will not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the Business Combination. This press release will also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities will be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, as amended, or an exemption therefrom.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on current expectations, forecasts, and assumptions that involve risks and uncertainties, which could cause actual outcomes and results to differ materially from those expressed or implied by these statements. Forward-looking statements include, but are not limited to, statements related to the development and potential of Phytanix Bio’s product candidates and the outcome of the proposed Business Combination. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Website: www.phytanixbio.com.
Investor Relations Contact:
Jeff Ramson
Media Relations Contact:
Ashlee Vogenthaler